Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 September 2020Website:
http://preludetx.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:02:23 GMTDividend
Analysts recommendations
Institutional Ownership
PRLD Latest News
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST)
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline
What type of business is Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
What sector is Prelude Therapeutics Incorporated in?
Prelude Therapeutics Incorporated is in the Healthcare sector
What industry is Prelude Therapeutics Incorporated in?
Prelude Therapeutics Incorporated is in the Biotechnology industry
What country is Prelude Therapeutics Incorporated from?
Prelude Therapeutics Incorporated is headquartered in United States
When did Prelude Therapeutics Incorporated go public?
Prelude Therapeutics Incorporated initial public offering (IPO) was on 25 September 2020
What is Prelude Therapeutics Incorporated website?
https://preludetx.com
Is Prelude Therapeutics Incorporated in the S&P 500?
No, Prelude Therapeutics Incorporated is not included in the S&P 500 index
Is Prelude Therapeutics Incorporated in the NASDAQ 100?
No, Prelude Therapeutics Incorporated is not included in the NASDAQ 100 index
Is Prelude Therapeutics Incorporated in the Dow Jones?
No, Prelude Therapeutics Incorporated is not included in the Dow Jones index
When was Prelude Therapeutics Incorporated the previous earnings report?
No data
When does Prelude Therapeutics Incorporated earnings report?
The next expected earnings date for Prelude Therapeutics Incorporated is 14 February 2025